首药控股(688197) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,000,000, a decrease compared to the previous year[4] - The net profit attributable to shareholders was a loss of CNY 50,751,013.40, an improvement from a loss of CNY 53,307,597.39 in the same period last year[4] - The net profit for Q1 2025 was CNY -50,645,324.22, compared to CNY -52,956,251.73 in Q1 2024, showing an improvement of approximately 4.36%[28] - The total comprehensive income for Q1 2025 was a loss of CNY 50,751,013.40, compared to a loss of CNY 53,307,597.39 in Q1 2024[18] - Net profit for Q1 2025 was a loss of CNY 50,751,013.40, an improvement from a loss of CNY 53,307,597.39 in Q1 2024, indicating a reduction in losses by approximately 4.8%[18] Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 62,848,399.58, worsening from a negative CNY 45,250,824.29 year-on-year[4] - Operating cash flow for Q1 2025 was negative at CNY -62,848,399.58, worsening from CNY -45,250,824.29 in Q1 2024[20] - Cash and cash equivalents at the end of Q1 2025 stood at CNY 20,363,311.37, down from CNY 534,209,428.53 at the end of Q4 2024[21] - Cash and cash equivalents at the end of Q1 2025 were CNY 19,937,010.09, down from CNY 534,173,832.12 at the end of Q1 2024[31] - The company reported a net cash outflow from financing activities of CNY -1,314,290.84 in Q1 2025[21] Assets and Liabilities - Total assets decreased by 6.18% to CNY 865,221,911.65 compared to the end of the previous year[5] - The company's total liabilities decreased from RMB 113,214,992.31 to RMB 106,959,812.11, reflecting a reduction of about 5.5%[15] - The company's total current assets were RMB 733,217,504.80, compared to RMB 779,798,182.90, showing a decline of around 6.0%[13] - The company's total non-current assets decreased from RMB 142,429,922.35 to RMB 132,004,406.85, a reduction of about 7.3%[14] - The total assets decreased from CNY 923,574,892.06 to CNY 869,487,866.16, a decline of approximately 5.86%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,297[8] - The largest shareholder, Li Wenjun, holds 49.05% of the shares, totaling 72,953,101 shares[9] - Shareholders' equity attributable to shareholders decreased by 6.27% to CNY 758,262,099.54[5] - The company's total equity attributable to shareholders decreased from RMB 809,013,112.94 to RMB 758,262,099.54, reflecting a decline of approximately 6.3%[15] - The company’s total equity decreased from CNY 810,196,740.75 to CNY 759,551,416.53, a decline of approximately 6.26%[25] Research and Development - Research and development expenses totaled CNY 53,635,759.01, representing 2,681.79% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 53,635,759.01, slightly up from CNY 53,553,272.74 in Q1 2024[17] - Research and development expenses for Q1 2025 were CNY 54,832,901.97, slightly increasing from CNY 54,569,339.56 in Q1 2024[28] Investment and Financing - Investment cash inflow for Q1 2025 was CNY 582,296,832.83, significantly higher than CNY 287,014,591.78 in Q1 2024, marking an increase of 103.3%[20] - The company recorded a financial expense of CNY -224,610.90 in Q1 2025, compared to CNY -2,624,611.32 in Q1 2024, indicating a significant reduction in financial costs[28] Inventory and Receivables - The company's accounts receivable increased significantly to RMB 1,900,000.00 from RMB 91,116.71, marking a substantial increase of over 2000%[13] - The company's inventory decreased from RMB 3,410,663.08 to RMB 1,587,703.81, indicating a reduction of approximately 53.5%[13] General Observations - The company has not reported any significant new product developments or market expansions during the reporting period[11] - Total operating costs increased to CNY 58,000,117.07 in Q1 2025 from CNY 56,883,837.15 in Q1 2024, representing a growth of 1.97%[17] - The basic and diluted earnings per share were both CNY -0.34, slightly improving from CNY -0.36 in the previous year[4]